CMS Secures China NMPA Approval for Renal Anaemia Drug Desidustat
Event summary
- China Medical System Holdings Ltd. (CMS) received NMPA approval for Desidustat Tablets, a novel oral HIF-PHI for treating renal anaemia in non-dialysis CKD patients, on March 13, 2026.
- Desidustat demonstrated superior efficacy over placebo in Phase III trials, maintaining Hb levels within target ranges long-term.
- CMS licensed Desidustat exclusively from Zydus Lifesciences under a 2020 agreement.
- The drug addresses a significant unmet need: only 8.2% of non-dialysis CKD anaemia patients in China achieve target Hb levels.
The big picture
This approval strengthens CMS’s nephrology portfolio alongside Velphoro, targeting China’s 120M+ CKD patients. The HIF-PHI class represents a strategic shift from injectable EPO therapies to oral alternatives, aligning with CMS’s innovation-driven specialty focus. Success here could validate its dual-engine R&D model and emerging-market expansion strategy.
What we're watching
- Commercialization Pace
- How quickly CMS can scale Desidustat’s adoption given its existing nephrology channel network and Velphoro synergy.
- Pipeline Execution
- Whether CMS can maintain momentum with 20+ projects in clinical trials while commercializing new approvals.
- Regional Expansion
- The pace at which CMS pursues Desidustat approvals beyond China and India.
Related topics